Streetbeat News

Regulatory

COUR

CPRI

DXCM

JOBY

MASI

SAM

SBSW

TBBK

TVGN

Several major stocks, including Capri Holdings, Coursera, and DexCom, experienced significant declines in pre-market trading. Capri's shares plummeted after a judge blocked its merger with Tapestry, while Coursera and DexCom fell due to disappointing financial guidance and results.

Portfolio Pulse from Avi Kapoor

October 25, 2024 | 1:14 pm

LSB

LakeShore Biopharma has received approval in China for a Phase III trial of its simplified four-dose YSJA rabies vaccine regimen. This aims to improve patient adherence and reduce costs while maintaining immunogenicity.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 12:34 pm

DERM

Journey Medical presented data on DFD-29 at the 44th Fall Clinical Dermatology Conference, highlighting its potential benefits over doxycycline for treating rosacea. The FDA is reviewing the New Drug Application for DFD-29, with a decision expected by November 4, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 12:32 pm

NINE

Nine Energy Service, Inc. has received a notice from the NYSE indicating non-compliance with listing standards due to its market capitalization and stockholders' equity falling below $50 million.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 12:31 pm

ALBT

Avalon GloboCare Corp. (NASDAQ:ALBT) has signed a memorandum of understanding with Qi Diagnostics to explore a strategic collaboration for developing a cannabis breathalyzer. The MOU grants Avalon a 120-day exclusivity period to negotiate a definitive agreement. The collaboration would focus on creating a prototype capable of detecting cannabis, leveraging Avalon's regulatory expertise. However, the terms of the agreement are not guaranteed.

Portfolio Pulse from Vandana Singh

October 25, 2024 | 12:31 pm

JNJ

Johnson & Johnson's SPECTREM study reveals that TREMFYA® (Guselkumab) effectively clears low BSA plaque psoriasis in special sites, achieving primary and secondary endpoints in a Phase 3b trial. The company also launched a clinical image library to assist in decision-making for diverse skin tones.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 12:08 pm

ROIV

Dermavant presented final data from the ADORING 3 LTE study on VTAMA cream, showing 51.9% of patients achieved complete disease clearance and remained treatment-free for about 80 days. The FDA PDUFA action date is expected in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 12:06 pm

EVLV

Evolv is conducting an internal investigation into its sales practices due to misconduct by certain personnel. The investigation focuses on extra-contractual terms affecting revenue recognition. Evolv is cooperating with an SEC investigation.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 12:04 pm

EVLV

Evolv Technology has announced that shareholders and others should not rely on certain previously issued financial statements. The company will delay filing its quarterly report.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 12:01 pm

EVLV

Trading for a company has been halted at 7:55:00 a.m. ET due to pending news. This could indicate significant upcoming announcements that may impact the stock price.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 11:55 am